Prima BioMed Announces Data From IMP321 AIPAC Clinical Trial in Breast Cancer
SYDNEY, AUSTRALIA--(Marketwired - Dec 21, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data from the AIPAC Phase IIb clinical trial for IMP321 in metastatic breast cancer (Active …